iTeos Therapeutics (ITOS)
(Real Time Quote from BATS)
$10.12 USD
+0.01 (0.10%)
Updated Aug 6, 2025 12:12 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITOS 10.12 +0.01(0.10%)
Will ITOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITOS
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
ITOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
Other News for ITOS
Ridgeback Capital Investments L.P. Acquires Significant Stake in ITeos Therapeutics Inc.
iTeos Therapeutics (ITOS) Downgraded Following Merger Agreement | ITOS Stock News
iTeos Therapeutics just downgraded at Piper Sandler, here's why
iTeos Therapeutics (ITOS) Agrees to Acquisition by Concentra Biosciences
Vor Bio appoints Cumbo, Detheux to board of directors